Anthony D Piscopio

This inventor holds 26 USPTO granted patents and 4 published patent applications, plus 2 CIPO patents and 4 EPO patents, primarily in Protein Deacetylase Inhibitors. Top assignees: Pfizer Corporation, Onkure, Inc., Array Biopharma Inc.. Active years: 1999-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Anthony D Piscopio. Retrieved from https://idiyas.com/inventor/anthony-d-piscopio

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 26 (Patent Applications = 4)

% Patents Active = 88.5

CIPO Patents = 2 (Patent Applications = 3)

EPO Patents = 4 (Patent Applications = 3)

Average Co-Inventor Count = 3.9

ph-index = 7

Forward Citations = 300(Granted Patents)

Location History:

Groton, CT (US) (2000)
Longmount, CO (US) (1999 - 2003)
Longmont, CO (US) (1999 - 2022)
Boulder, CO (US) (2011 - 2023)

Company Filing History:

University of Colorado

where one patent can have more than one assignee

Years Active: 1999-2025

Loading Chart...

Areas of Expertise:

Cyclic Depsipeptides

Benzimidazole Compounds

Protein Deacetylase Inhibitors

AKT Protein Kinase Inhibitors

Heterocyclic Hydroxamic Acids

Arylsulfonyl Hydroxamic Acids

Substituted Chromanol Derivatives

Thioester Prodrugs

Histone Deacetylases

MMP Inhibitors

TNF Inhibitors

Dual Protein Kinase Inhibitors

26 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12252511 - Process for the preparation of cyclic depsipeptides (2025-03-18),

2. 11739123 - Process for the preparation of cyclic depsipeptides (2023-08-29),

3. 11339150 - Benzimidazole compounds as HDAC6 inhibitors (2022-05-24),

4. 11203602 - Thioester prodrugs of macrocycles as inhibitors of histone deacetylases (2021-12-21),

5. 11053284 - Process for the preparation of cyclic depsipeptides (2021-07-06),

6. 10689419 - Process for the preparation of cyclic depsipeptides (2020-06-23),

7. 10508122 - Heterocyclic hydroxamic acids as protein deacetylase inhibitors and dual protein deacetylase-protein kinase inhibitors and methods of use thereof (2019-12-17),

8. RE47690 - Heterocyclic hydroxamic acids as protein deacetylase inhibitors and dual protein deacetylase-protein kinase inhibitors and methods of use thereof (2019-11-04),

9. 10100089 - Process for the preparation of cyclic depsipeptides (2018-10-16),

10. 9840520 - Heterocyclic hydroxamic acids as protein deacetylase inhibitors and dual protein deacetylase-protein kinase inhibitors and methods of use thereof (2017-12-12),

11. 9024040 - Processes for preparing benzimidazole compounds (2015-05-05),

12. 8680114 - AKT protein kinase inhibitors (2014-03-25),

13. 8501956 - Benzimidazole compounds (2013-08-06),

14. 8383832 - Process for preparing benzimidazole compounds (2013-02-26),

15. 8039637 - Process for preparing benzimidazole compounds (2011-10-18),

Title: The Innovative Journey of Anthony D. Piscopio in Pharmaceuticals

Introduction: Anthony D. Piscopio, based in Longmont, CO, is a prolific inventor with an impressive portfolio of 25 patents. His work primarily revolves around novel therapeutic compounds, particularly in the fields of cyclic depsipeptides and HDAC6 inhibitors. Piscopio's contributions are noteworthy, demonstrating a commitment to advancing pharmaceutical sciences.

Latest Patents: Among his latest innovations, Anthony has developed processes for the preparation of cyclic depsipeptides. These processes detail the steps for creating compounds of specified formulas, providing vital intermediates for further research and application. Additionally, he has worked on benzimidazole compounds, presenting selective HDAC6 inhibitors aimed at treating diseases linked to HDAC6 activity. These compounds, described by specific formulas, are significant in the ongoing battle against various health disorders.

Career Highlights: Anthony D. Piscopio has had a distinguished career with notable stints at prestigious companies. He has made significant contributions during his tenure at Pfizer Corporation and Onkure, Inc., where his expertise in drug development has been instrumental in pushing the frontiers of pharmaceutical innovation.

Collaborations: Throughout his career, Piscopio has collaborated with prominent colleagues in the industry. Noteworthy coworkers include Mark Anthony Dombroski and Kevin Koch, who have contributed to his progressive work environment, enhancing the innovation culture in their respective fields.

Conclusion: Anthony D. Piscopio exemplifies the spirit of innovation within the pharmaceutical industry. His patents and collaborative efforts reflect a dedication to improving healthcare solutions. As he continues to push the boundaries of scientific inquiry, his contributions remain crucial to the evolution of medical treatments and therapies.

Profile summary based on public USPTO records.